Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRL Stock Forecast 2026-2027
$218.82
Current Price
$10.77B
Market Cap
Buy 11
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to CRL Price Targets
+14.2%
To High Target of $250.00
-6.3%
To Median Target of $205.00
-29.2%
To Low Target of $155.00
CRL Price Momentum
+1.3%
1 Week Change
+13.4%
1 Month Change
+15.1%
1 Year Change
+9.7%
Year-to-Date Change
-1.6%
From 52W High of $222.37
+138.2%
From 52W Low of $91.86
📊 TOP ANALYST CALLS
Did CRL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Charles River is one of their latest high-conviction picks.
Latest CRL Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, CRL has a bullish consensus with a median price target of $205.00 (ranging from $155.00 to $250.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $218.82, the median forecast implies a -6.3% downside. This outlook is supported by 11 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Dan Brennan at UBS, projecting a 14.2% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 29.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRL Analyst Ratings
11
Buy
7
Hold
0
Sell
CRL Price Target Range
Low
$155.00
Average
$205.00
High
$250.00
Current: $218.82
Latest CRL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 18, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $200.00 |
| Dec 15, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $215.00 |
| Dec 15, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $190.00 |
| Nov 11, 2025 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Maintains | $185.00 |
| Nov 10, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $197.00 |
| Nov 6, 2025 | Baird | Eric Coldwell | Outperform | Upgrade | $199.00 |
| Nov 6, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $210.00 |
| Nov 6, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $165.00 |
| Oct 17, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $174.00 |
| Oct 6, 2025 | William Blair | Matt Larew | Outperform | Upgrade | $N/A |
| Oct 3, 2025 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $200.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Overweight | Upgrade | $195.00 |
| Sep 9, 2025 | Jefferies | David Windley | Buy | Upgrade | $195.00 |
| Aug 8, 2025 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $190.00 |
| Aug 7, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $165.00 |
| Aug 7, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $160.00 |
| Jul 9, 2025 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $180.00 |
| Jul 9, 2025 | Citigroup | Patrick Donnelly | Buy | Upgrade | $200.00 |
| May 23, 2025 | Redburn Atlantic | Jamie Clark | Buy | Upgrade | $182.00 |
| May 8, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $140.00 |
Charles River Laboratories International, Inc. (CRL) Competitors
The following stocks are similar to Charles River based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CRL
Charles River
mkt cap
10.87B
Charles River Laboratories International, Inc. (CRL) Financial Data
Charles River Laboratories International, Inc. has a market capitalization of $10.77B with a P/E ratio of 681.3x. The company generates $4.02B in trailing twelve-month revenue with a -2.0% profit margin.
Revenue growth is -0.5% quarter-over-quarter, while maintaining an operating margin of +15.0% and return on equity of -2.2%.
Valuation Metrics
Market Cap
$10.77B
Enterprise Value
$13.34B
P/E Ratio
681.3x
PEG Ratio
-39.7x
Price/Sales
2.7x
Growth & Margins
Revenue Growth (YoY)
-0.5%
Gross Margin
+33.7%
Operating Margin
+15.0%
Net Margin
-2.0%
EPS Growth
-21.9%
Financial Health
Cash/Price Ratio
+1.9%
Current Ratio
1.4x
Debt/Equity
76.3x
ROE
-2.2%
ROA
+4.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Charles River Laboratories International, Inc. (CRL) Business Model
About Charles River Laboratories International, Inc.
What They Do
Provides laboratory services for drug development.
Business Model
The company generates revenue by offering specialized laboratory services to the pharmaceutical and biotechnology industries, focusing on drug discovery and development. Its business model is divided into three segments: research models and services, discovery and safety assessment, and manufacturing support, each addressing different needs in the drug development process.
Additional Information
Operating in over 20 countries, Charles River Laboratories serves a diverse clientele including life sciences firms, academic institutions, and government entities. With a strong emphasis on scientific expertise and ethical research practices, the company plays a crucial role in the regulatory approval process for new drugs and therapies.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
18,700
CEO
Mr. James C. Foster J.D.
Country
United States
IPO Year
2000
Website
www.criver.comCharles River Laboratories International, Inc. (CRL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
What Makes Charles River (CRL) a New Buy Stock
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jan 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Charles River Laboratories will acquire a key supplier of non-human primates for approximately $510 million to enhance control over procurement for drug safety testing.
Why It Matters
Charles River's acquisition of a key supplier enhances its supply chain control, potentially improving margins and stability in drug testing operations, which can drive investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Charles River Laboratories has released business updates, providing insights that may be relevant for investors. Further details can be found in their official communication.
Why It Matters
Charles River Laboratories' business updates could signal changes in financial performance or strategy, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan
5 days ago
Quick Summary
Charles River Laboratories announced the planned retirement of James C. Foster and outlined a succession plan for the CEO position.
Why It Matters
Leadership changes can impact company strategy and performance. Investors may reassess the stock's stability and future growth potential amid uncertainty surrounding the new CEO.
Source: Business Wire
Market Sentiment:
Neutral
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
7 days ago
Quick Summary
Charles River (CRL) has reached a 52-week high. Investors may assess the company's fundamentals to determine the potential for future gains.
Why It Matters
Charles River at a 52-week high signals strong performance; analyzing fundamentals can indicate potential for continued growth or risks, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Charles River (CRL) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may lead to a potential increase in share price.
Why It Matters
Charles River's Zacks Rank #2 upgrade signals strong earnings potential, likely boosting investor confidence and driving stock demand.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Charles River is benefiting from strong RMS demand, strategic partnerships, and solid finances, but anticipates macroeconomic and competitive pressures in 2025.
Why It Matters
Strong RMS demand and strategic partnerships boost Charles River’s outlook, but macroeconomic and competitive challenges may impact future performance, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CRL Stock
What is Charles River Laboratories International, Inc.'s (CRL) stock forecast for 2026?
Based on our analysis of 33 Wall Street analysts, Charles River Laboratories International, Inc. (CRL) has a median price target of $205.00. The highest price target is $250.00 and the lowest is $155.00.
Is CRL stock a good investment in 2026?
According to current analyst ratings, CRL has 11 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $218.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRL stock?
Wall Street analysts predict CRL stock could reach $205.00 in the next 12 months. This represents a -6.3% decrease from the current price of $218.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Charles River Laboratories International, Inc.'s business model?
The company generates revenue by offering specialized laboratory services to the pharmaceutical and biotechnology industries, focusing on drug discovery and development. Its business model is divided into three segments: research models and services, discovery and safety assessment, and manufacturing support, each addressing different needs in the drug development process.
What is the highest forecasted price for CRL Charles River Laboratories International, Inc.?
The highest price target for CRL is $250.00 from Dan Brennan at UBS, which represents a 14.2% increase from the current price of $218.82.
What is the lowest forecasted price for CRL Charles River Laboratories International, Inc.?
The lowest price target for CRL is $155.00 from Luke Sergott at Barclays, which represents a -29.2% decrease from the current price of $218.82.
What is the overall CRL consensus from analysts for Charles River Laboratories International, Inc.?
The overall analyst consensus for CRL is bullish. Out of 33 Wall Street analysts, 11 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $205.00.
How accurate are CRL stock price projections?
Stock price projections, including those for Charles River Laboratories International, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 12:44 PM UTC